Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 5, 2010, Pages 1088-1100

  Romanitan, Mihaela O ^a,b   Popescu, Bogdan O ^a,b   Spulber, Ştefan ^c   Bâjenaru, Ovidiu ^b   Popescu, Laurenţiu M ^a,b   Winblad, Bengt ^c   Bogdanovic, Nenad ^c  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer' disease; Claudins; Tight junctions; Vascular dementia

Indexed keywords

CLAUDIN;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN; CELL COUNT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIGENE FAMILY; MULTIINFARCT DEMENTIA; NERVE CELL; OLIGODENDROGLIA; PATHOLOGY; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASTROCYTES; BRAIN; CELL COUNT; CLAUDINS; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; NEURONS; OLIGODENDROGLIA;

EID: 77954769168     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00999.x     Document Type: Article

References (85)

1. Popescu BO, Toescu EC, Popescu LM. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci. 2009, 283:99-106.
2. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004, 286:C1213-28.
3. Rubin LL. The blood-brain barrier in and out of cell culture. Curr Opin Neurobiol. 1991, 1:360-3.
4. Martin-Padura I, Lostaglio S, Scheneemann M. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and regulates monocytes transmigration. J Cell Biol. 1998, 142:117-27.
5. Furuse M, Hirase T, Itoh M. Occludin: a novel integral membrane protein localizing at the tight junctions. J Cell Biol. 1993, 123:1777-88.
6. Sonoda N, Furuse M, Sasaki H. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J Cell Biol. 1999, 147:195-204.
7. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001, 2:285-93.
8. Nitta T, Hata M, Gotoh S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003, 161:653-60.
9. Morita K, Furuse M, Fujimoto K. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA. 1999, 96:511-6.
10. Huber JD, Witt KA, Hom S. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol. 2001, 280:H1241-8.
11. Wolburg H, Wolburg-Buchholz K, Kraus J. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 2003, 105:586-92.
12. Lippoldt A, Liebner S, Andbjer B. Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and -5 expression by protein kinase C. Neuro Report. 2000, 11:1427-31.
13. Furuse M, Furuse K, Sasaki H. Converison of Zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney cells. J Cell Biol. 2001, 153:263-72.
14. Amasheh S, Meiri N, Gitter AH. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci. 2002, 115:4969-76.
15. Morita K, Sasaki H, Fujimoto K. Claudin-11/OSP- based tight junctions of myelin sheaths in brain and Sertoli cells in testis. J Cell Biol. 1999, 145:579-88.
16. Bronstein JM, Tiwari-Woodruff S, Buznikov AG. Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease. J Neurosci Res. 2000, 59:706-11.
17. Wolburg H, Wolburg-Buchholz K, Liebner S. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci Lett. 2001, 307:77-80.
18. Miyamori H, Takino T, Kobayashi Y. Claudin promotes activation of Pro-MMP-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem. 2001, 276:28204-11.
19. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999, 22:11-28.
20. Nag S. Patophysiology of blood-brain barier breakdown. Methods Mol Med. 2003, 89:97-119.
21. Kreuter J. Neuroparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001, 47:65-81.
22. Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr. 2003, 15:47-52.
23. Thal DR, Griffin WS, Braak H. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med. 2008, 12:1848-62.
24. Marco S, Skaper S. Amyloid beta-peptide (1-42) alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett. 2006, 401:219-24.
25. Findley MK, Koval M. Regulation and roles for claudin-family tight junction proteins. IUBMB Life. 2009, 61:431-7.
26. Bauer H, Stelzhammer W, Fuchs R. Astrocytes and Neurons Express the Tight Junction-Specific Protein Occludin in vitro. Exp Cell Res. 1999, 250:434-8.
27. Romaniţan MO, Popescu BO, Winblad B. Occludin is overexpressed in Alzheimer's disease and vascular dementia. J Cell Mol Med. 2007, 11:569-79.
28. Bailey TL, Rivara CB, Rocher AB. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res. 2004, 26:573-8.
29. Viswanathan A, Gray F, Bousser MG. Cortical neuronal apoptosis in CADASIL. Stroke. 2008, 37:2690-5.
30. Committee on Nomenclature and Statistics. Diagnostical and statistical manual of mental disorders 1994, 133-45. American Psychiatric Association, 4th ed, Washington, DC, American Psychiatric Association, pp
31. McKhann G, Drachmann D, Folstein M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work group under the auspices of the Department of Health and Human Services. Neurology. 1984, 34:939-44.
32. Bogdanovic N, Morris JH. Diagnostic criteria for Alzheimer's disease in multicentre brain banking. Neuropathological diagnostic criteria for brain banking 1995, 20-9. Cruz-Sanches FF, Ravid RCuzner ML. In, editors, Amsterdam, IOS Press, pp
33. Consensus recommendations for the post-mortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997, 18:S1-2. National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
34. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of rat hippocampus using the optical fractionator. Anat Rec. 1991, 231:482-97.
35. Lasn H, Winblad B, Bogdanovic N. Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease. J Cell Mol Med. 2006, 10:145-56.
36. Förster C. Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 2008, 130:55-70.
37. Kröll S, El-Gindi J, Thanabalasundaram G. Control of the blood-brain barrier by glucocorticoids and the cells of the neurovascular unit. Ann NY Acad Sci. 2009, 1165:228-39.
38. Ronaldson PT, Demarco KM, Sanchez-Covarrubias L. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab. 2009, 29:1084-98.
39. Argaw AT, Gurfein BT, Zhang Y. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA. 2009, 106:1977-82.
40. Bake S, Friedman JA, Sohrabji F. Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc Res. 2009, 78:413-24.
41. Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol. 2006, 16:181-8.
42. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. 2001, 64:575-611.
43. de Jong GI, de Vos RAI, Jansen Steur ENH. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease. Ann NY Acad Sci. 1997, 826:56-74.
44. Shin JS, Hyun SY, Kim DH. Chronic hypoperfusion increases claudin-3 immunoreactivity in rat brain. Neurosci Lett. 2008, 445:144-8.
45. Chen G, Bridenbaugh EA, Akintola AD. Increased susceptibility of aging kidney to ischemic injury: identification of candidate genes changed during aging, but corrected by caloric restriction. Am J Physiol Renal Physiol. 2007, 293:F1272-81.
46. Van Elzen R, Moens L, Dewilde S. Expression profiling of the cerebral ischemic and hypoxic response. Expert Rev Proteomics. 2008, 5:263-82.
47. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008, 57:178-201.
48. Gottfries CG, Balldin J, Blennow K. Hypothalamic dysfunction in dementia. J Neural Transm Suppl. 1994, 43:203-9.
49. Maeda K, Tanimoto K, Terada T. Elevated urinary free cortisol in patients with dementia. Neurobiol Aging. 1991, 12:161-3.
50. Green KN, Billi$ngs LM, Roozendaal B. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006, 26:9047-56.
51. Popescu BO, Popescu LM. Neuronal apoptosis triggered by anti-Fas (CD95, APO-1) antibody is enhanced by dexamethasone. J Med Biochem. 2000, 4:1-14.
52. Burek M, Förster CY. Cloning and characterization of the murine claudin-5 promoter. Mol Cell Endocrinol. 2009, 298:19-24.
53. Tipsmark CK, Jorgensen C, Brande-Lavridsen N. Effects of cortisol, growth hormone and prolactin on gill claudin expression in Atlantic salmon. Gen Comp Endocrinol. 2009, 163:270-7.
54. Landfield PW, Blalock EM, Chen KC. A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. Curr Alzheimer Res. 2007, 4:205-12.
55. de Quervain DJ, Poirier R, Wollmer MA. Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet. 2004, 13:47-52.
56. Tai LM, Holloway KA, Male DK. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med. 2009, 10.1111/j.1582-4934.2009.00717.x, DOI
57. Lee HT, Chang YC, Tu YF. VEGF-A/VEGFR-2 signaling leading to cAMP response element-binding protein phosphorylation is a shared pathway underlying the protective effect of preconditioning on neurons and endothelial cells. J Neurosci. 2009, 29:4356-68.
58. Moser KV, Humpel C. Vascular endothelial growth factor counteracts NMDA-induced cell death of adult cholinergic neurons in rat basal nucleus of Meynert. Brain Res Bull. 2005, 65:125-31.
59. Provias J, Jeynes B. Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase. Curr Neurovasc Res. 2008, 5:199-205.
60. Mateo I, Llorca J, Infante J. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand. 2007, 116:56-8.
61. Town T, Laouar Y, Pittenger C. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008, 14:681-687.
62. Malaguarnera L, Motta M, Di Rosa M. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology. 2006, 26:307-12.
63. Tarkowski E, Issa R, Sjögren M. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002, 23:237-43.
64. Hu Z, Fan J, Zeng L. Transient cerebral ischemia leads to TGF-beta2 expression in Golgi apparatus organelles. Curr Neurovasc Res. 2008, 5:178-184.
65. Howe KL, Reardon C, Wang A. Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. Am J Pathol. 2005, 167:1587-97.
66. Stopa EG, Gonzalez AM, Chorsky R. Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun. 1990, 171:690-6.
67. Bendfeldt K, Radojevic V, Kapfhammer J. Basic fibroblast growth factor modulates density of blood vessels and preserves tight junctions in organotypic cortical cultures of mice: a new in vitro model of the blood-brain barrier. J Neurosci. 2007, 27:3260-7.
68. Cowburn RF, O'Neill C, Bonkale WL. Receptor-G-protein signalling in Alzheimer's disease. Biochem Soc Symp. 2001, 67:163-75.
69. Angelow S, Zeni P, Höhn B. Phorbol ester induced short- and long-term permeabilization of the blood-CSF barrier in vitro. Brain Res. 2005, 1063:168-79.
70. Stamatovic SM, Dimitrijevic OB, Keep RF. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem. 2006, 281:8379-88.
71. Jin JK, Ahn BH, Na YJ. Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease. Neurobiol Aging. 2007, 28:1015-27.
72. Jin JK, Kim NH, Lee YJ. Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer's disease patients. Neurosci Lett. 2006, 407:263-7.
73. Umemura K, Yamashita N, Yu X. Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients. Neurosci Lett. 2006, 400:97-100.
74. Liu Y, Zhang YW, Wang X. Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1. J Biol Chem. 2009, 284:12145-52.
75. Zeiller C, Mebarek S, Jaafar R. Phospholipase D2 regulates endothelial permeability through cytoskeleton reorganization and occludin downregulation. Biochim Biophys Acta. 2009, 1793:1236-49.
76. Popescu AT, Vidulescu C, Stanciu CL. Selective protection by phosphatidic acid against staurosporine-induced neuronal apoptosis. J Cell Mol Med. 2002, 6:433-438.
77. Steiner MR, Holtsberg FW, Keller JN. Lysophosphatidic acid induction of neuronal apoptosis and necrosis. Ann NY Acad Sci. 2000, 905:132-41.
78. Wessells H, Sullivan CJ, Tsubota Y. Transcriptional profiling of human cavernosal endothelial cells reveals distinctive cell adhesion phenotype and role for claudin 11 in vacular barrier function. Physiol Genomics. 2009, 39:100-8.
79. Pike CJ, Carroll JC, Rosario ER. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol. 2009, 30:239-58.
80. Kaitu'u-Lino TJ, Sluka P, Foo CF. Claudin-11 expression and localisation is regulated by androgens in rat Sertoli cells in vitro. Reproduction. 2007, 133:1169-79.
81. Ponholzer A, Madersbacher S, Rauchenwald M. Serum androgen levels and their association to depression and Alzheimer dementia in a cohort of 75-year-old men over 5 years: results of the VITA study. Int J Impot Res. 2009, 21:187-91.
82. Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease. J Neuroendocrinol. 2000, 12:351-4.
83. Rimon E, Sasson R, Dantes A. Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int J Oncol. 2004, 24:1325-38.
84. Popescu BO, Ankarcrona M. Neurons bearing presenilins: weapons for defense or suicide. J Cell Mol Med. 2000, 4:249-261.
85. Casadesus G, Garrett MR, Webber KM. The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease. Drugs R D. 2006, 7:187-93.